Strategic Facility Expansion Cambrex is actively investing in expanding its manufacturing footprint across North America and Europe, notably with a $120 million API plant in Iowa and significant facility upgrades in Milan and Coffeyville. This demonstrates ongoing capacity enhancements and opportunities for partnerships in high-volume drug substance production.

Advanced Technology Adoption With capabilities in continuous flow, peptide synthesis, and highly potent APIs, Cambrex offers cutting-edge manufacturing solutions suitable for clients developing complex and innovative molecules, making it an ideal partner for companies seeking advanced production technologies.

Robust R&D Investment Recent investments into R&D and asset expansion, including a $150 million project, highlight Cambrex’s commitment to innovation and complex small-molecule and peptide services, presenting opportunities to collaborate on cutting-edge drug development projects.

Market Growth & Industry Position As a mid-sized global CDMO with revenues between $500 million and $1 billion and a broad service portfolio, Cambrex is well-positioned to support growing biopharmaceutical and small-molecule markets, especially for clients needing reliable supply chain solutions and scalable manufacturing.

Recognition & Industry Leadership The recent award received by key personnel underscores Cambrex’s innovative capacity and industry recognition, which can be leveraged to build credibility and establish trust with prospective clients seeking a proven partner for high-quality pharmaceutical manufacturing.